 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Atara Biotherapeutics, Inc. Nasdaq: ATRA, a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer of Atara, will participate at three upcoming virtual conferences. Cowen 5th Annual IO Next Summit Fireside chat on Monday, November 15, 2021 